Clinical Therapeutics

Editorial comment
pp. 1-1(1)
Author: Walson P.D.

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions
pp. 2-25(24)
Author: Warren Beach J.

The role of clobetasol propionate emollient 0.05 1129n the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses
pp. 26-39(14)
Author: Gordon M.L.

Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies
pp. 40-57(18)
Authors: Epstein J.B.; Polsky B.

Risperidone versus haloperidol: I. meta-analysis of efficacy and safety
pp. 58-71(14)
Authors: Davies A.; Adena M.A.; Keks N.A.; Catts S.V.; Lambert T.; Schweitzer I.

Clinical comparison of cefaclor twice daily versus amoxicillin-clavulanate or erythromycin three times daily in the treatment of patients with streptococcal pharyngitis
pp. 72-79(8)
Authors: Esposito S.; De Ritis G.; D'Errico G.; Noviello S.; Ianniello F.

Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product
pp. 80-87(8)
Authors: Jordan W.P.; Atkinson L.E.; Lai C.

Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis
pp. 88-100(13)
Authors: McAdoo M.A.; Rice K.; Gordon G.R.; Sahn S.A.

Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia
pp. 101-109(9)
Authors: Mobley D.F.; Dias N.; Levenstein M.

Effect of nabumetone on hemostasis during arthroscopic knee surgery
pp. 110-124(15)
Authors: Schnitzer T.J.; Donahue J.R.; Toomey E.P.; Holtby R.M.; Scuderi G.R.; Adams P.L.; Poland M.P.

Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells
pp. 125-140(16)
Authors: Somwar R.; Sweeney G.; Ramlal T.; Klip A.

Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia
pp. 141-155(15)
Authors: Pryka R.; Kowalsky S.; Haverstock D.

Pharmaceutical economics & health policy - Editorial comment
pp. 158-159(2)
Author: Sclar D.A.

Potential biases in assessing the risks of pharmacotherapy due to mismeasurement of drug exposure
pp. 160-168(9)
Authors: Leader S.; Mallick R.

Costs and duration of care for lower extremity ulcers in patients with diabetes
pp. 169-181(13)
Authors: Sedory Holzer S.E.; Camerota A.; Martens L.; Cuerdon T.; Crystal-Peters J.; Zagari M.

A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery
pp. 182-195(14)
Authors: Hawkins D.W.; Langley P.C.; Krueger K.P.

Risperidone versus haloperidol: II. Cost-effectiveness
pp. 196-213(18)
Authors: Davies A.; Langley P.C.; Keks N.A.; Catts S.V.; Lambert T.; Schweitzer I.

Correction
pp. 214-214(1)